CCO
0.003
50%
NAE
0.001
-50%
M2R
0.003
50%
AOK
0.002
-33.3%
TOU
0.003
50%
ARV
0.003
-25%
AVE
0.021
40%
MQR
0.006
-25%
BLU
0.004
33.3%
KM1
0.08
-23.8%
HIQ
0.008
33.3%
COI
0.1
-23.1%
HYD
0.004
33.3%
AHN
0.004
-20%
M2M
0.01
25%
KTA
0.004
-20%
TGH
0.02
25%
XGL
0.008
-20%
BNZ
2.63
24.1%
BTE
0.04
-18.4%
UM1
0.145
20.8%
NOR
0.031
-18.4%
LKO
0.615
20.6%
LIS
0.115
-17.9%
AZI
0.024
20%
AVD
0.1
-16.7%
SIX
0.084
20%
ENL
0.005
-16.7%
NH3
0.11
17%
FEL
0.005
-16.7%
AM5
0.007
16.7%
RBX
0.03
-16.7%
GLL
0.007
16.7%
VIT
0.022
-15.4%
LMG
0.014
16.7%
T3D
0.035
-14.6%
PL9
0.007
16.7%
BNL
0.006
-14.3%
SIS
0.007
16.7%
MEM
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT U.S. FDA accepted new drug application

Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX